At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
Summary
The purpose of this role is to provide leadership to the Trial Master File (TMF) Study Leads staff in order to ensure TMF compliance and inspection readiness for active studies at all times. The Study Lead Line Head reports into the Global TMF Process Lead and will support that role in creating/achieving TMF Process optimization.
Responsibilities
Supervisory responsibility for TMF Study Leads, provides training, support, and coaching as required
Oversees activities across studies to ensure compliance with TMF requirements
In collaboration with the TMF Study Leads, supports BMS audit/inspection readiness activities and consults with all relevant functions within and outside GCO to ensure readiness
Support the Global TMF Process Lead in developing Work Instructions, templates, plans and work assignments. Attend/represent the Global TMF Process Lead at key meetings
Support the Global TMF Process Lead in developing & implementing various TMF Process Initiatives to achieve quality and compliance.
Provides leadership, infrastructure, and subject matter expertise to the TMF organization
Prioritizes book of work for the TMF Study Leads and assign resources based on study portfolio changes
Grows and develops internal staff to strengthen the organization
Collaborates across multiple functions supporting clinical trial processes to ensure adherence to regulatory requirements for maintenance of compliant TMFs and identify efficiency opportunities
Assists and trains internal and CRO teams on TMF processes
Maintains continuous knowledge of the regulatory requirements and industry trends related to TMF compliance
Communicate as appropriate with relevant stakeholders
Along with Global TMF process Lead, leads and participates in continuous improvement initiatives related to clinical trial documentation and TMF compliance
Address gaps in TMF compliance as highlighted by Quality metrics and KPI
Degree Requirements
Minimum of a Bachelor degree in Science, Pharmacy, or related field
Experience Requirements
At least 5-7 years of experience in health sciences or related industry
Strong working knowledge of TMF, eTMF and clinical document management systems.
Strong organizational and technical ability. Demonstrated Excel, PowerPoint, and SharePoint skills.
Comprehensive knowledge of local and international regulatory guidelines/requirements pertinent to TMF Management.
Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
Summit, NJ
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.
The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.